Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 129, 189-197
Abstract
No abstract availableKeywords
Funding Information
- Stanley Medical Research Institute (10T-1401)
This publication has 47 references indexed in Scilit:
- Higher Baseline Proinflammatory Cytokines Mark Poor Antidepressant Response in Bipolar DisorderThe Journal of Clinical Psychiatry, 2017
- Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorderJournal of Affective Disorders, 2014
- Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factorsSocial Psychiatry and Psychiatric Epidemiology, 2014
- Chemokines in bipolar disorder: Trait or state?European Archives of Psychiatry and Clinical Neuroscience, 2012
- Abnormalities in serum chemokine levels in euthymic patients with Bipolar DisorderBrain, Behavior, and Immunity, 2009
- CSF and plasma cytokines at delivery and postpartum mood disturbancesJournal of Affective Disorders, 2009
- Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: Functional effect of MCP‐1/CCL2 on calcium mobilization in primary cultured neuronsJournal of Comparative Neurology, 2005
- Expression of chemokines and their receptors in human and simian astrocytes: Evidence for a central role of TNFα and IFNγ in CXCR4 and CCR5 modulationGlia, 2003
- Functional expression of CCR2 by human fetal astrocytesJournal of Neuroscience Research, 2002
- Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brainJournal of Neurochemistry, 2002